This trial is evaluating whether Mogamulizumab will improve 1 primary outcome and 6 secondary outcomes in patients with refractory, primary Cutaneous T-Cell Non-Hodgkin Lymphoma. Measurement will happen over the course of Baseline to day 84.
This trial requires 12 total participants across 1 different treatment group
This trial involves a single treatment. Mogamulizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Granulomatous slack skin affects approximately 1 in 600 people. It usually occurs on and around the thighs and buttocks and tends to be associated with diabetes. The presence of granulomatous slack skin is associated with a significantly higher risk of developing skin cancer." - Anonymous Online Contributor
"Granulomatous slack skin is a disorder in which a variety of treatment approaches have been used, with only one proven successful treatment—dexamethasone combined with other medications. We discuss this case in this report along with three others." - Anonymous Online Contributor
"GSS is a monomorphic condition that can often be diagnosed by clinical examination. This is not surprising as the clinical feature of this condition is usually absent." - Anonymous Online Contributor
"It appears that granulomatous slack skin may be the result of an allergic response to a fungal or atopic agent which may be present in grain from maize, rice and wheat, or alternatively, this condition may be an allergic reaction to a food or substance (possibly flour). Treatment may be topical application of corticosteroidal creams. Further studies are required to investigate this, especially in southern parts of the continent." - Anonymous Online Contributor
"It is necessary to be aware of the most relevant signs of SLGS. In fact, even in cases where patients are asymptomatic, the disease can be associated with changes in appearance of the skin caused by the infiltration of macrophages and lymphocytes." - Anonymous Online Contributor
"No randomized controlled trials or systematic reviews have been found to directly compare the effectiveness of the current treatment options for GSHS. We offer suggestions to the clinician or patient on treatments to attempt first in managing this disorder." - Anonymous Online Contributor
"The prognosis of GSKS is related to severity and location of the condition and to the patient's overall health and condition. GSKS is a difficult disease to treat as there is frequently recurrence of symptoms. It may recur multiple times in a single patient. However, the prognosis remains satisfactory and should not be discouraged. GSKS remains a disease that can be treated successfully with medications and, rarely, laser photocoagulation. Most patients with GSKS obtain symptomatic resolution. A minority of patients may choose to undergo excision and may do well. Although it has been shown to not significantly affect survival, the overall survival is poorer in patients with GSKS compared with patients without GSKS." - Anonymous Online Contributor
"Mogamulizumab is an effective treatment for recalcitrant sclerosing skin diseases including granulomatous slack skin as well as pemphigus, pemphigoid, bullous pemphigoid, dermatitis herpetiformis, pemphigus foliaceus, eczema herpeticum, and dermatomyositis. It can also be used to treat pemphigus vulgaris and cutaneous lupus erythematosus in combination with glucocorticoids or immunosuppressive drugs." - Anonymous Online Contributor
"The severity of GSKS is not limited to the extent of the disease. In addition to large lesions, this disorder can present with extensive atrophy or deformity. The treatment decisions in patients with GSKS depend on the extent and severity of atrophy and deformity." - Anonymous Online Contributor
"Mogamulizumab can induce various kinds of common side effects such as rash, conjunctive irritation, facial swelling, alopecia, muscle pain and abdominal discomfort. A few case reports have mentioned the associations between mogamulizumab and severe cardiotoxicity, which necessitates discontinuation." - Anonymous Online Contributor
"Mogamulizumab treatment was well tolerated for this study population. The use of mogamulizumab increased the quality of life in patients with granulomatous slack skin which was associated with the clinical improvement in patients." - Anonymous Online Contributor
"This is the first prospective analysis of mogamulizumab's safety and tolerability in people with active Crohn's disease. Results from a recent clinical trial add to clinical data from clinical trials in people with Crohn's disease and demonstrate the utility of prospective, observational, and population-based studies for assessing adverse events and drug discontinuation." - Anonymous Online Contributor